Benjamin M. Parsons - Concepedia

Author

Benjamin M. Parsons

Also Known As

B M Parsons, B Parsons, B. M. Parsons, B. Parsons, Ben M Parsons, Ben M. Parsons, Ben Parsons, Benjamin M Parsons, Benjamin M. Parsons, Benjamin Marshall Parsons

252

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

Gundersen Health System The University of Texas MD Anderson Cancer Center Marqués de Valdecilla University Hospital University Hospital of Basel Northwestern University

About

Benjamin M. Parsons is an author at Gundersen Health System specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	3.6K
2	Health Sciences	4	4	2.8K
3	Public Health	2	2	28
4	Engineering	1	1	39
5	Biostatistics	1	1	18

Benjamin M. Parsons

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial Shaji Kumar, Susanna Jacobus, Adam D. Cohen, The Lancet Oncology Hematological MalignancyOncologyMarrow TransplantationTransplantationImmunology	2020	243
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era Andrew M. Evens, Irene Helenowski, Erika Ramsdale, Blood	2011	158
Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma Qing Ye, Zijun Y. Xu‐Monette, Alexandar Tzankov, Oncotarget Hematological MalignancyLymphoid NeoplasiaMyc TranslocationPrognostic ImpactConcurrent Myc	2015	112
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma Zijun Y. Xu‐Monette, Ling Li, John C. Byrd, Blood	2016	107
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Blood	2024	106
Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome Chadi Nabhan, Sonali M. Smith, Irene Helenowski, British Journal of Haematology Lymphoid NeoplasiaGeriatric OncologyAgingGeriatricsMedicine	2011	94
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium Lijuan Deng, Zijun Y. Xu‐Monette, Sanam Loghavi, Leukemia Hematological MalignancyLymphoid NeoplasiaUrologyMedicinePrimary Testicular	2015	83
Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database* Devalkumar J. Rajyaguru, Chaithanya Bhaskar, Andrew J. Borgert, Leukemia & lymphoma/Leukemia and lymphoma PathologyDlbcl NosUnited StatesHematological MalignancyPopulation-based Study	2017	83
Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma Zijun Y. Xu‐Monette, Qipan Deng, Ganiraju C. Manyam, Clinical Cancer Research	2016	65

Page 1